1 unchanged sentence
Incorporation by Reference
−Removed: Amended and Restated By-Laws of Cellectar Biosciences, Inc., effective as of March 11, 2025
−Removed: March 17, 2025
+Added: Form of Pre-Funded Common Stock Purchase Warrant
+Added: Form of Series A Common Stock Purchase Warrant
+Added: Form of Series B Common Stock Purchase Warrant
+Added: Form of Series C Common Stock Purchase Warrant
+Added: Form of Placement Agent Warrant
+Added: Form of Securities Purchase Agreement, dated May 4, 2026, by and among the Company and the institutional investors identified on the signatures pages thereto
+Added: Form of Securities Purchase Agreement, dated May 4, 2026, by and among the Company and the members of management identified on the signatures pages thereto
+Added: Form of Registration Rights Agreement, dated May 4, 2026, by and among the Company and the investors identified on the signature pages thereto
+Added: Form of Placement Agency Agreement, dated May 4, 2026, by and between the Company and Ladenburg Thalmann & Co.
+Added: Letter Agreement, dated May 4, 2026, by and between the Company and Nantahala Capital Management, LLC
+Added: Cellectar Biosciences, Inc.
+Added: 2021 Stock Incentive Plan, as Amended
+Added: July 10, 2026
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
5 unchanged sentences
CELLECTAR BIOSCIENCES, INC.
+Added: August 13, 2026
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 13, 2026
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.